Fresh analysis reveals that people who come off new slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end traditional lifestyle regimens.
Published data in a major health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications need to be informed of the risk of quick weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment mass in about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Researchers note that individuals who shed pounds through diet and exercise typically see a less rapid creep back—around 100 grams monthly—once they finish.
Understanding the Quick Regain
Doctors suggest the way of the jabs explains the amplified regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
Health authorities suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, considering the high risk of weight regain, the treatment might need to be life-long.
This opinion is supported by pharmaceutical companies, who state that the results "emphasize the long-term character of obesity," akin to managing conditions like hypertension.
User Accounts
Users who have discontinued the jabs describe a powerful return of appetite.
"It was like a trigger flipping and you become extremely hungry," recalled a patient.
This difficulty is exacerbated if individuals have not adopted permanent dietary or behavioural modifications during therapy.
Growing Use
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Use is greater among women than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while the jabs are powerful agents for weight loss, they are not a permanent cure and long-term success likely depends on combined behavioural management.
